Jeffrey Alan Bluestone

Jeffrey A. Bluestone, Ph.D., is Co-Founder and Advisor of Sonoma Biotherapeutics and A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology (Emeritus) at the University of California, San Francisco (UCSF), where he founded and directs the UCSF Diabetes Center. He previously served as UCSF's Executive Vice Chancellor and Provost and as Founding Director and CEO of the Parker Institute for Cancer Immunotherapy. Dr. Bluestone made groundbreaking contributions demonstrating that CTLA-4 functions as a negative regulator of T-cell activation, representing a major paradigm shift in immunology. In 1995, collaborating with Arlene Sharpe, he co-authored a landmark Immunity paper using CTLA-4-deficient mice, establishing CTLA-4's critical role in down-regulating T-cell activation and maintaining immune homeostasis. His systematic studies of the CD28/B7 costimulatory system established the two-signal model of T-cell activation, and his work defining CTLA-4's biochemical function led directly to FDA approval of ipilimumab (Yervoy), the first CTLA-4 checkpoint blockade drug, revolutionizing cancer treatment. Beyond foundational immunology, Bluestone has driven clinical translation of immunotherapies. He was among the early developers of teplizumab, an anti-CD3 monoclonal antibody that became the first FDA-approved disease-modifying therapy for type 1 diabetes (2022), proven to delay disease onset by approximately two years. In 2000, he established the UCSF Diabetes Center to translate diabetes research into patient therapies. His laboratory pioneered regulatory T cell (Treg) biology, developing strategies to harness these immunosuppressive cells for treating type 1 diabetes and autoimmune diseases. In 2019, he co-founded Sonoma Biotherapeutics to develop engineered Treg cell therapies. Dr. Bluestone earned his Ph.D. from Cornell University (1980) and has published over 500 papers advancing understanding of T-cell activation and immune tolerance in autoimmunity, transplantation, and cancer. He was elected to the National Academy of Sciences (2023), National Academy of Medicine (2018), and American Academy of Arts and Sciences (2002). His honors include the AAI-Steinman Award (2022), William B. Coley Award (2014), and mentorship awards from AAI and AST.

Jeffrey A. Bluestone博士(哲学博士)是Sonoma Biotherapeutics联合创始人和顾问,加州大学旧金山分校(UCSF) A.W.和Mary Margaret Clausen新陈代谢与内分泌学杰出教授(荣休),他创立并领导UCSF糖尿病中心。他曾担任UCSF执行副校长兼教务长,以及Parker癌症免疫治疗研究所创始主任和首席执行官。 Bluestone博士证明CTLA-4作为T细胞活化负性调节因子发挥作用,做出了开创性贡献,代表免疫学领域的重大范式转变。1995年,他与Arlene Sharpe合作在Immunity发表里程碑论文,使用CTLA-4缺陷小鼠确立CTLA-4在下调T细胞活化和维持免疫稳态中的关键作用。他对CD28/B7共刺激系统的系统研究建立了T细胞活化的双信号模型,他定义CTLA-4生化功能的工作直接促成ipilimumab (Yervoy) 获FDA批准,这是首个CTLA-4检查点阻断药物,彻底改变了癌症治疗。 除基础免疫学外,Bluestone积极推动免疫疗法临床转化。他是teplizumab早期开发者之一,这一抗CD3单克隆抗体成为首个获FDA批准的1型糖尿病疾病修饰疗法(2022),被证明可延缓疾病发病约2年。2000年,他建立UCSF糖尿病中心,将糖尿病研究转化为患者疗法。他的实验室开创了调节性T细胞(Treg)生物学研究,开发利用这些免疫抑制细胞治疗1型糖尿病和自身免疫疾病的策略。2019年,他联合创立Sonoma Biotherapeutics开发工程化Treg细胞疗法。 Bluestone获Cornell大学哲学博士(1980),发表500+篇论文,推进了自身免疫、移植和癌症中T细胞活化和免疫耐受的理解。2023年当选美国国家科学院院士,2018年当选国家医学院院士,2002年当选美国艺术与科学院院士。他的荣誉包括2022年AAI-Steinman奖、2014年William B. Coley奖以及AAI和AST的导师奖。